Four-Mechanism Gene Therapy Shows Slower GA Lesion Growth

The phase 1/2 study also showed no serious adverse events

By: Jay Chhablani, MD, Michael A. Singer, MD

Retinal Physician November 21, 2025

Clinical Report: Four-Mechanism Gene Therapy Shows Slower GA Lesion Growth

Overview

A phase 1/2 study of Ocugen's OCU410 gene therapy for geographic atrophy (GA) demonstrated a 27% reduction in lesion growth compared to fellow eyes, with no serious adverse events reported. The therapy employs a four-mechanism approach, showing promise in both safety and efficacy.

Background

Geographic atrophy (GA) is a significant cause of vision loss in age-related macular degeneration (AMD), and current treatment options are limited. Gene therapy represents a novel approach to potentially slow disease progression and improve patient outcomes. Understanding the safety and efficacy of such therapies is crucial for advancing treatment strategies in retinal diseases.

Data Highlights

{'Phase 1': 'Clarify that the 23% reduction is from Phase 1 results, not Phase 2.'}

Key Findings

{'procedure-related side effects': 'Add specific examples of typical side effects.'}

Clinical Implications

{'integration': 'Provide guidance on how to discuss this therapy with patients.'}

Conclusion

The phase 1/2 study of OCU410 gene therapy indicates a promising approach to managing geographic atrophy, warranting further investigation in larger trials to confirm these findings.

PentaVision

Retinal Physician